Skip to content

Ketamine research published in 2025

Page 22 of 39: studies 421 to 440 of 780, newest first. Back to the ketamine overview

Studies

Ketamine-Assisted Psychotherapy for Treatment-Resistant Depression: a Systematic Review

Current Treatment Options in Psychiatry May 5, 2025 Ana Malta Gomes, Filipa Novais 3 citations

Abstract Purpose of the review Treatment-resistant depression (TRD) is a challenging condition characterized by minimal improvement despite two or more antidepressant trials. Ketamine-assisted psychotherapy (KAP) integrates the rapid antidepressant effects of ketamine with psychotherapy to enhance and sustain therapeutic outcomes. This systematic review evaluates the effectiveness of KAP in...

Association of low-dose ketamine with hallucinations in critically ill patients: a target trial emulation.

Intensive care medicine May 5, 2025 Ary Serpa Neto, Marcus Young, Jian Wen Chan et al. 9 citations

Ketamine use is a potentially modifiable risk factor for hallucinations. We aimed to use target trial emulation to investigate the association between low-dose ketamine and development of hallucinations in critically ill patients in the intensive care unit (ICU). Retrospective study using data from a university affiliated ICU in Melbourne, Australia. Application of marginal structural models...

DOI: 10.1007/s00134-025-07926-w (opens in new tab) Full text (opens in new tab) Delirium Hallucination Ketamine side effects Intensive care medicine +3

Ketamine evokes acute behavioral effects via μ-opioid receptor expressing neurons of the central amygdala.

Biological Psychiatry May 5, 2025 Matthew B Pomrenze, Sam Vaillancourt, Pierre Llorach et al. 11 citations

Ketamine has anesthetic, analgesic, and antidepressant properties which may involve multiple neuromodulatory systems. In humans, the opioid receptor (OR) antagonist naltrexone blocks the antidepressant effect of ketamine. This mechanism may differentiate ketamine from other NMDA receptor antagonists. Animal models that reflect OR-dependent behavioral effects of ketamine may shed light on the...

DOI: 10.1016/j.biopsych.2025.04.020 (opens in new tab) Full text (opens in new tab) Antidepressant Central amygdala Mu opioid receptor Naltrexone +5

Role of CaMKII/CREB pathway in rapid-antidepressant-like effect: comparison of ketamine with rapastinel.

Experimental Brain Research May 4, 2025 Ceyda Özler, Esra Özkan, Narges Shomalizadeh et al. 1 citation

Recent studies in mouse models have demonstrated that ketamine and rapastinel induce rapid-acting and sustained antidepressant effects in major depressive disorder (MDD). However, it remains unclear how ketamine's and rapastinel's opposing mechanisms of action-NMDAR antagonist and NMDAR positive allosteric modulator, respectively-result in similar antidepressant-like effects. Furthermore,...

Treatment-resistant depression and intranasal esketamine: Spanish clinical consensus on practical aspects

The European Journal of Psychiatry May 2, 2025 Josep Antoni Ramos‐quiroga, Fernando Mora, Silvia Arostegui et al. 4 citations

Pharmacological management of major depressive disorder has traditionally relied on antidepressants targeting the monoaminergic pathway. Treatment-resistant depression (TRD) patients have been frequently excluded from registrational trials, resulting in a lack of clear clinical recommendations for an optimised management. In recent years, treatments based on other mechanisms of action have been...

The effect of esketamine on postoperative anxiety and depression in patients with thyroid cancer: A randomized, double-blind, placebo-controlled, parallel-group trial.

Medicine May 2, 2025 Xiaobo Bi, Junchao Dai, Jin Li 8 citations

This study aimed to investigate the effects of a single intravenous injection of esketamine during general anesthesia on postoperative anxiety and depression in patients with thyroid cancer. In this randomized, double-blind, placebo-controlled, parallel-group trial, eighty female patients with thyroid cancer were scheduled to undergo surgery under general anesthesia. The patients were randomly...

DOI: 10.1097/MD.0000000000042284 (opens in new tab) Full text (opens in new tab) Affective symptoms Postoperative complication Thyroid cancer surgery Esketamine therapy +3

Attitudes and Perceptions of Portuguese Psychiatrists and Psychologists on the Clinical Use of Ketamine.

Acta Médica Portuguesa May 2, 2025 Pedro Mota, Jorge Encantado, Laura C. Carvalho et al. 1 citation

Ketamine has garnered attention for its rapid efficacy in alleviating depressive symptoms in treatment-resistant depression, offering a novel mechanism as a non-monoaminergic agent. Despite its potential, limited research has explored mental health professionals' perspectives on its use. This study assesses the attitudes, knowledge, and concerns of Portuguese psychiatrists and psychologists...

Ketamine for unipolar major depression: critical examination of antidepressant effects

BJPsych Advances May 1, 2025 Aditya Patel

SUMMARYThis critical appraisal of a Cochrane Review assesses the efficacy of ketamine for treating unipolar major depressive disorder. The review included 31 randomised controlled trials involving ketamine. Results indicate that intravenous (i.v.) ketamine significantly improves antidepressant response compared with i.v. saline and, to a lesser extent, i.v. midazolam within 24–72 h. However,...

Clinical treatment of cluster headache with the serotonergic indoleamine psychedelics psilocybin and LSD and with ketamine: A case series

Cephalalgia Reports May 1, 2025 Jonathan A. Leighton, Chieh Grace Lau, Aisha Savdo et al. 2 citations

Background Cluster headache is an excruciating condition for which standard treatments are usually insufficient. Evidence has accumulated that serotonergic psychedelic indoleamines including psilocybin and LSD can be effective in preventing attacks. Methods In this case series, nine patients with episodic and chronic cluster headache that didn’t respond to conventional treatments were treated...

Hepatobiliary Complications Associated With Ketamine Use: Clinical Insights and Future Directions.

Cureus May 1, 2025 Hafiza Wajeeha Waheed, Muhammad R Ashraf, Talha Sajjad et al.

Ketamine has been utilized in various medical contexts, particularly for its effects on the nervous system. Over time, its applications have expanded beyond its initial use, with emerging interest in its potential to influence mood and cognition. In certain clinical populations, it has been associated with a rapid reduction in depressive symptoms and suicidal thoughts, particularly when...

DOI: 10.7759/cureus.84974 (opens in new tab) Full text (opens in new tab) Biliary duct abnormalities Chronic ketamine user Drug-induced hepatotoxicity Drug-induced liver failure +2

Prophylactic (R,S)-Ketamine and (2S,6S)-Hydroxynorketamine Decrease Fear Expression by Differentially Modulating Fear Neural Ensembles.

Biological Psychiatry May 1, 2025 Alessia Mastrodonato, Michelle Jin, Noelle Kee et al. 5 citations

We previously reported that a single injection of (R,S)-ketamine or its metabolite (2S,6S)-hydroxynorketamine (HNK) prior to stress attenuated learned fear. However, whether these drugs attenuate learned fear through divergent or convergent effects on neural activity remains to be determined. 129S6/SvEv male mice were injected with saline, (R,S)-ketamine, or (2S,6S)-HNK 1 week before a 3-shock...

DOI: 10.1016/j.biopsych.2024.09.024 (opens in new tab) Full text (opens in new tab) Depression Contextual fear conditioning Metabolite Neural network +5

A Comparison of Ketamine to Midazolam for the Management of Acute Behavioral Disturbance in the Out-of-Hospital Setting.

Annals of emergency medicine May 1, 2025 Maeve Muldowney, Catherine R Counts, Madison C Maider et al. 2 citations

Acute behavioral disturbance is characterized by altered mental status and psychomotor agitation. Pharmacological sedation may be required, risking potential respiratory compromise. We compared the need for emergent airway support following administration of midazolam or ketamine to treat acute behavioral disturbance in the out-of-hospital setting. In this retrospective cohort study of patients...

DOI: 10.1016/j.annemergmed.2024.09.003 (opens in new tab) Full text (opens in new tab) Emergency-medicine Sedation-drugs Patient-safety Acute-agitation +1

Symptom modulation and tolerability of intravenous ketamine in treatment-resistant bipolar depression: A retrospective study.

Journal of Affective Disorders May 1, 2025 Alessandro Cuomo, Simone Pardossi, Giovanni Barillà et al. 7 citations

Ketamine's use in treating bipolar depression must account for risks, such as switching to manic episodes or worsening symptoms. This study examines ketamine's impact on depressive symptoms, focusing on 'inner tension,' 'sleep reduction,' and 'suicidal ideation' over four weeks in treatment-resistant bipolar disorder (TR-BD) patients. Fifty-nine patients with TR-BD were treated consecutively...

DOI: 10.1016/j.jad.2025.01.059 (opens in new tab) Full text (opens in new tab) Bipolar disorder Mental health treatment Ketamine therapy Bipolar depression +2

Esketamine alleviates cognitive impairment signs induced by modified electroconvulsive therapy in a depression rat model via the KLF4/p38 MAPK pathway.

Journal of Affective Disorders May 1, 2025 Xiaohui Zhou, Li Zhang, Weiwei Gao et al. 4 citations

Depression is a common and serious psychiatric disorder with significant impacts on individuals. Modified electroconvulsive therapy (MECT) is an established treatment for severe and treatment-resistant depression, but its cognitive side effects, particularly memory impairments, limit its use. Esketamine (ESK), an FDA-approved antidepressant, has shown neuroprotective effects. However, its role...

DOI: 10.1016/j.jad.2025.02.012 (opens in new tab) Full text (opens in new tab) Cognitive impairment Modified electroconvulsive therapy Neuroprotection Depression treatment +2

Ketamine in insulin resistance: Pharmacokinetics, cardiovascular implications and cellular effects on cardiomyocytes.

Diabetes, Obesity & Metabolism May 1, 2025 Ariana Ramirez, Stephanie Howes, Robert Chilton 3 citations

Ketamine, a dissociative anaesthetic, has expanded its clinical use beyond anaesthesia to pain management and treatment-resistant depression. As an N-methyl-d-aspartate receptor antagonist, ketamine disrupts the excitatory neurotransmission via interaction with the opioid, alpha-amino-3-hydroxy-5-methyl-4-isooxazole-propionic acid receptor and serotonin pathways, contributing to its broad...

DOI: 10.1111/dom.16248 (opens in new tab) Full text (opens in new tab) Cardiovascular disease Diabetes complications Drug mechanism Insulin resistance +5

REM density predicts rapid antidepressant response to ketamine in individuals with treatment-resistant depression.

Neuropsychopharmacology May 1, 2025 Mina Kheirkhah, Wallace C. Duncan, Qiaoping Yuan et al. 6 citations

Abnormalities during rapid eye movement (REM) sleep contribute to the pathophysiology of major depressive disorder (MDD), but few studies have explored the relationship between REM sleep and treatment-resistant depression (TRD). In MDD, REM sleep abnormalities often manifest as alterations in total night REM Density (RD), RD in the first REM period (RD1), and REM Latency (RL). Among these, RD1...

A new module in the drug development process: preclinical multi-center randomized controlled trial of R-ketamine on alcohol relapse.

Neuropsychopharmacology May 1, 2025 Marcus W. Meinhardt, Ivan Skorodumov, Jérôme Jeanblanc et al. 8 citations

The drug development process in psychiatry faces significant challenges due to low reproducibility rates in animal testing, which often leads to translation failures. To address this issue, we introduce a new approach in psychiatric drug development: a preclinical randomized controlled trial (preRCT). To demonstrate its potential utility, we conducted a multi-center preRCT using the alcohol...

DOI: 10.1038/s41386-025-02071-w (opens in new tab) Full text (opens in new tab) Addiction treatment Ketamine therapy Alcohol dependence Gender medicine +1

Patient preference effects in a randomized comparative effectiveness study of electroconvulsive therapy and ketamine for treatment resistant depression: An ELEKT-D trial secondary analysis.

Psychiatry Research May 1, 2025 Gerard Sanacora, Brian S. Barnett, Bo Hu et al. 2 citations

Previous studies have shown patient preference can have large effects on treatment adherence and patient satisfaction. However, the direct effects of matching treatment with patient preference on efficacy and safety outcomes remain unclear. We aimed to evaluate the effects of patient preference and preference-matching on efficacy, adverse events, and adherence to electroconvulsive therapy (ECT)...

DOI: 10.1016/j.psychres.2025.116411 (opens in new tab) Full text (opens in new tab) Patient preference matching Contextual Depression treatment Electroconvulsive therapy ect +2

Tusi but not 2C: A Miami-Dade medical examiner case series highlighting the variable drug composition in colored powder paraphernalia.

Journal of Forensic Sciences May 1, 2025 Diane M Moore, Alexander D Giachetti, M Elizabeth Zaney et al. 3 citations

Eight fatalities between September 2020 and July 2024 in Miami-Dade County involving the ingestion of colored powders, referred to as "tusi," "tucibi," or "pink cocaine," are reported. For each case, a description of the terminal event, the postmortem toxicology findings, the cause and manner of death, and the chemical composition of the "tusi" powder(s) found on or near the decedent are...

Rapid hippocampal synaptic potentiation induced by ketamine metabolite (2R,6R)-hydroxynorketamine persistently primes synaptic plasticity.

Neuropsychopharmacology May 1, 2025 Kyle A Brown, Musa I Ajibola, Todd D Gould 13 citations

The pharmacologically active (R,S)-ketamine (ketamine) metabolite (2 R,6 R)-hydroxynorketamine (HNK) maintains ketamine's preclinical antidepressant profile without adverse effects. While hypotheses have been proposed to explain how ketamine and its metabolites initiate their antidepressant-relevant effects, it remains unclear how sustained therapeutic actions arise following drug elimination....

DOI: 10.1038/s41386-025-02085-4 (opens in new tab) Full text (opens in new tab) Mental-health Pharmacology Depression-treatment Brain-research